Related Experiment Video
Updated: Nov 30, 2025
A Stably Established Two-Point Injection of Lysophosphatidylcholine-Induced Focal Demyelination Model in Mice
Published on: May 11, 2022
Anti-MOG-associated demyelinating disorders: two sides of the same coin
Giorgia Teresa Maniscalco1,2, Lia Allegorico3, Gennaro Alfieri4
1Multiple Sclerosis Center, "A. Cardarelli" Hospital, Naples, Italy. gtmaniscalco@libero.it.
Background:
Anti-myelin oligodendrocyte glycoprotein antibody-associated disorders (MOGAD) are new emerging diseases with heterogeneous course, treatment, response, and prognosis.
Case Report:
We herein present 2 cases with antibodies to MOG, one with a cerebellar/brainstem monophasic syndrome which partially improved after treatment, and the other with an optic neuritis onset then relapsed with cortical encephalitis and presented a subsequent complete recovery. We further discuss elements possibly associated with disease heterogeneity and influencing treatment choices.
Conclusions:
MOGAD is an extremely variable disease which can relapse and accumulate disability over time. An early diagnosis and correct timely treatment is fundamental to improve clinical outcome.
Related Concept Videos
01:20Myasthenia Gravis: Overview and Treatment
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
01:29Autoimmune Disorders
Concept and Mechanism of Autoimmune Diseases
The immune...